245 related articles for article (PubMed ID: 17308033)
1. Analogs of methyllycaconitine as novel noncompetitive inhibitors of nicotinic receptors: pharmacological characterization, computational modeling, and pharmacophore development.
McKay DB; Chang C; González-Cestari TF; McKay SB; El-Hajj RA; Bryant DL; Zhu MX; Swaan PW; Arason KM; Pulipaka AB; Orac CM; Bergmeier SC
Mol Pharmacol; 2007 May; 71(5):1288-97. PubMed ID: 17308033
[TBL] [Abstract][Full Text] [Related]
2. Structure activity studies of ring E analogues of methyllycaconitine. Part 2: Synthesis of antagonists to the alpha3beta4* nicotinic acetylcholine receptors through modifications to the ester.
Bergmeier SC; Ismail KA; Arason KM; McKay S; Bryant DL; McKay DB
Bioorg Med Chem Lett; 2004 Jul; 14(14):3739-42. PubMed ID: 15203153
[TBL] [Abstract][Full Text] [Related]
3. N-n-alkylpyridinium analogs, a novel class of nicotinic receptor antagonists: selective inhibition of nicotine-evoked [3H] dopamine overflow from superfused rat striatal slices.
Grinevich VP; Crooks PA; Sumithran SP; Haubner AJ; Ayers JT; Dwoskin LP
J Pharmacol Exp Ther; 2003 Sep; 306(3):1011-20. PubMed ID: 12766255
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity studies with ring E analogues of methyllycaconitine on bovine adrenal alpha3beta4* nicotinic receptors.
Bryant DL; Free RB; Thomasy SM; Lapinsky DJ; Ismail KA; McKay SB; Bergmeier SC; McKay DB
Neurosci Res; 2002 Jan; 42(1):57-63. PubMed ID: 11814609
[TBL] [Abstract][Full Text] [Related]
5. Ring E analogs of methyllycaconitine (MLA) as novel nicotinic antagonists.
Bergmeier SC; Lapinsky DJ; Free RB; McKay DB
Bioorg Med Chem Lett; 1999 Aug; 9(15):2263-6. PubMed ID: 10465558
[TBL] [Abstract][Full Text] [Related]
6. Effect of novel negative allosteric modulators of neuronal nicotinic receptors on cells expressing native and recombinant nicotinic receptors: implications for drug discovery.
González-Cestari TF; Henderson BJ; Pavlovicz RE; McKay SB; El-Hajj RA; Pulipaka AB; Orac CM; Reed DD; Boyd RT; Zhu MX; Li C; Bergmeier SC; McKay DB
J Pharmacol Exp Ther; 2009 Feb; 328(2):504-15. PubMed ID: 18984653
[TBL] [Abstract][Full Text] [Related]
7. Interaction of noncompetitive inhibitors with an immobilized alpha3beta4 nicotinic acetylcholine receptor investigated by affinity chromatography, quantitative-structure activity relationship analysis, and molecular docking.
Jozwiak K; Ravichandran S; Collins JR; Wainer IW
J Med Chem; 2004 Jul; 47(16):4008-21. PubMed ID: 15267239
[TBL] [Abstract][Full Text] [Related]
8. Blockade of rat alpha3beta4 nicotinic receptor function by methadone, its metabolites, and structural analogs.
Xiao Y; Smith RD; Caruso FS; Kellar KJ
J Pharmacol Exp Ther; 2001 Oct; 299(1):366-71. PubMed ID: 11561100
[TBL] [Abstract][Full Text] [Related]
9. QSAR modeling of mono- and bis-quaternary ammonium salts that act as antagonists at neuronal nicotinic acetylcholine receptors mediating dopamine release.
Zheng F; Bayram E; Sumithran SP; Ayers JT; Zhan CG; Schmitt JD; Dwoskin LP; Crooks PA
Bioorg Med Chem; 2006 May; 14(9):3017-37. PubMed ID: 16431111
[TBL] [Abstract][Full Text] [Related]
10. Effects of methyllycaconitine and related analogues on bovine adrenal alpha3beta4* nicotinic acetylcholine receptors.
Bryant DL; Free RB; Thomasy SM; Lapinsky DJ; Ismail KA; Arason KM; Bergmeier SC; McKay DB
Ann N Y Acad Sci; 2002 Oct; 971():139-41. PubMed ID: 12438104
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological properties of alpha 9 alpha 10 nicotinic acetylcholine receptors revealed by heterologous expression of subunit chimeras.
Baker ER; Zwart R; Sher E; Millar NS
Mol Pharmacol; 2004 Feb; 65(2):453-60. PubMed ID: 14742688
[TBL] [Abstract][Full Text] [Related]
12. Identifying the binding site of novel methyllycaconitine (MLA) analogs at α4β2 nicotinic acetylcholine receptors.
Quek GX; Lin D; Halliday JI; Absalom N; Ambrus JI; Thompson AJ; Lochner M; Lummis SC; McLeod MD; Chebib M
ACS Chem Neurosci; 2010 Dec; 1(12):796-809. PubMed ID: 22778816
[TBL] [Abstract][Full Text] [Related]
13. Different interaction between the agonist JN403 and the competitive antagonist methyllycaconitine with the human alpha7 nicotinic acetylcholine receptor.
Arias HR; Gu RX; Feuerbach D; Wei DQ
Biochemistry; 2010 May; 49(19):4169-80. PubMed ID: 20377277
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms and binding site locations for noncompetitive antagonists of nicotinic acetylcholine receptors.
Arias HR; Bhumireddy P; Bouzat C
Int J Biochem Cell Biol; 2006; 38(8):1254-76. PubMed ID: 16520081
[TBL] [Abstract][Full Text] [Related]
15. Methyllycaconitine analogues have mixed antagonist effects at nicotinic acetylcholine receptors.
Barker D; Lin DH; Carland JE; Chu CP; Chebib M; Brimble MA; Savage GP; McLeod MD
Bioorg Med Chem; 2005 Jul; 13(14):4565-75. PubMed ID: 15922601
[TBL] [Abstract][Full Text] [Related]
16. Receptor protection studies comparing recombinant and native nicotinic receptors: Evidence for a subpopulation of mecamylamine-sensitive native alpha3beta4* nicotinic receptors.
Free RB; Kaser DJ; Boyd RT; McKay DB
Neurosci Lett; 2006 Jan; 392(1-2):135-9. PubMed ID: 16198480
[TBL] [Abstract][Full Text] [Related]
17. Characterization and three-dimensional structure determination of psi-conotoxin Piiif, a novel noncompetitive antagonist of nicotinic acetylcholine receptors.
Van Wagoner RM; Jacobsen RB; Olivera BM; Ireland CM
Biochemistry; 2003 Jun; 42(21):6353-62. PubMed ID: 12767216
[TBL] [Abstract][Full Text] [Related]
18. Expression of native alpha3beta4* neuronal nicotinic receptors: binding and functional studies investigating turnover of surface and intracellular receptor populations.
Free RB; McKay SB; Gottlieb PD; Boyd RT; McKay DB
Mol Pharmacol; 2005 Jun; 67(6):2040-8. PubMed ID: 15772292
[TBL] [Abstract][Full Text] [Related]
19. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
Parenti MD; Pacchioni S; Ferrari AM; Rastelli G
J Med Chem; 2004 Aug; 47(17):4258-67. PubMed ID: 15293997
[TBL] [Abstract][Full Text] [Related]
20. Development of subtype-selective ligands as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release.
Crooks PA; Ayers JT; Xu R; Sumithran SP; Grinevich VP; Wilkins LH; Deaciuc AG; Allen DD; Dwoskin LP
Bioorg Med Chem Lett; 2004 Apr; 14(8):1869-74. PubMed ID: 15050618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
